Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Multicenter, Comparative, Double-blind, Parallel Study to Evaluate the Efficacy and Safety of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) With Reference Pertuzumab (Perjeta®, Genentech Inc.,) in Patients With HER2 Positive Metastatic Breast Cancer

NCT05283837 is registered in ClinicalTrials.gov with Zydus Lifesciences Limited as lead sponsor.

NCT NCT05283837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05283837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Multicenter, Comparative, Double-blind, Parallel Study to Evaluate the Efficacy and Safety of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) With Reference Pertuzumab (Perjeta®, Genentech Inc.,) in Patients With HER2 Positive Metastatic Breast Cancer
Lead sponsor
Zydus Lifesciences Limited
Phase
Phase 3
Overall status
Completed
Start date
September 26, 2022
Completion date
September 6, 2023
Enrollment
268 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer